Fundraising Fox
Silo Pharma
NASDAQ: SILOSarasota, US · Nevada corporation
Find your way into Silo Pharma
Sign up to see every warm intro you have to Silo Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Silo Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing novel formulations of traditional and psychedelic therapeutics for underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes programs for PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis, pursued via the FDA 505(b)(2) pathway in collaboration with academic research partners.
Founders & leadership
DR
Daniel RyweckChief Financial Officer
LS
Leonard SchillerNamed on SEC filing
VP
Van ParkerNamed on SEC filing
Board
KM
Kevin MunozBoard director
WL
Wayne LinsleyBoard director
JP
Jeff PavellBoard director
Reported raises · per SEC filings
Form D private placements$15.2M disclosed across 7 of 9 rounds · 2018–2026
▶$4MraisedJul 2026 · 4 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJul 2026 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
- Eric WeisblumExecutive Officer, Director
- Daniel RyweckExecutive Officer
- Wayne LinsleyDirector
- Kevin MunozDirector
- Jeff PavellDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Sales commissions
- $300K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.3MraisedAug 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$2.3MraisedAug 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin MunozDirector
- Eric WeisblumExecutive Officer, Director
- Daniel RyweckExecutive Officer
- Wayne LinsleyDirector
- Jeff PavellDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Sales commissions
- $157.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2.1MraisedJun 2024 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedJun 2024 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeff PavellDirector
- Kevin MunozDirector
- Wayne LinsleyDirector
- Eric WeisblumExecutive Officer, Director
- Daniel RyweckExecutive Officer
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- Sales commissions
- $150K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4.3MraisedFeb 2021 · 47 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedFeb 2021 · 47 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wayne D. LinsleyDirector
- Kevin MunozDirector
- Eric WeisblumExecutive Officer, Director
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- Sales commissions
- $404.4K
- Placement agents
- Katalyst Securities LLC, Bradley Woods & Co. Ltd.
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedMay 2020 · 46 investors · RetailingRule 506(b)
▶$2.4MraisedMay 2020 · 46 investors · Retailing
Rule 506(b)Officers, directors & promoters on the filing
- Wayne D. LinsleyDirector
- Eric WeisblumExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.4M
- Sales commissions
- $173.9K
- Placement agents
- The Special Equities Group, LLC a division of Bradley Woods & Co. Ltd., Katalyst Securities, LLC
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$115KraisedDec 2019 · 3 investors · RetailingRule 506(b)
▶$115KraisedDec 2019 · 3 investors · Retailing
Rule 506(b)Officers, directors & promoters on the filing
- Eric WeisblumExecutive Officer, Director
- Leonard SchillerDirector
- Joel StoneDirector
- Van ParkerDirector
- Offering amount
- $2M
- Amount sold
- $115K
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.5KraisedDec 2018 · RetailingRule 506(b)
▶$24.5KraisedDec 2018 · Retailing
Rule 506(b)Officers, directors & promoters on the filing
- Eric WeisblumExecutive Officer, Director
- Leonard SchillerDirector
- Van ParkerDirector
- Offering amount
- $200K
- Amount sold
- $24.5K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$4.7Mvaluation at IPOMay 2025 · $0.60/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 9
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanksFinancial analysis and stock research platform.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
KrakenKraken 360 Investments provides capital and launch infrastructure to blockchain protocols in pre-token and early post-token phases, offering custody, staking, treasury, and liquidity services alongside fundraising support.
Companies working in the same space as Silo Pharma.
In the news
Frequently asked questions
- What does Silo Pharma do?
- Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing novel formulations of traditional and psychedelic therapeutics for underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes programs for PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis, pursued via the FDA 505(b)(2) pathway in collaboration with academic research partners.
- Who founded Silo Pharma?
- Silo Pharma was founded by Eric Weisblum.
- How much funding has Silo Pharma raised?
- Silo Pharma has disclosed $15.2M raised across 7 of its 9 known rounds.
- Where is Silo Pharma headquartered?
- Silo Pharma is headquartered in Sarasota, US.